BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5

BTIG analyst Julian Harrison has maintained a 'Buy' rating on Connect Biopharma Holdings (NASDAQ: CNTB) but has lowered the price target from $10 to $5. This adjustment reflects a change in outlook for the company's stock performance.